WO2023015102A1 - Procédé de production d'isolat de cbd - Google Patents

Procédé de production d'isolat de cbd Download PDF

Info

Publication number
WO2023015102A1
WO2023015102A1 PCT/US2022/073669 US2022073669W WO2023015102A1 WO 2023015102 A1 WO2023015102 A1 WO 2023015102A1 US 2022073669 W US2022073669 W US 2022073669W WO 2023015102 A1 WO2023015102 A1 WO 2023015102A1
Authority
WO
WIPO (PCT)
Prior art keywords
vessel
measure
temperature
approximately
mixture
Prior art date
Application number
PCT/US2022/073669
Other languages
English (en)
Inventor
Duane DRINKWINE
Donal R. SCHMIDT
Sean P. BERRIER
Original Assignee
Rapid Therapeutic Sciences Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapid Therapeutic Sciences Laboratories, Inc. filed Critical Rapid Therapeutic Sciences Laboratories, Inc.
Publication of WO2023015102A1 publication Critical patent/WO2023015102A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol

Definitions

  • the background of the invention relates to metered dose, inhaler-related products, formulations, and methods of manufacturing.
  • the inventors seek to provide, vis-a-vis prior methods, formulations and administrative devices, improved methods of formulation and associated optimal delivery means associated with the therapeutic use of cannabidiol (CBD).
  • CBD cannabidiol
  • CBD is known to be a therapeutic agent, inter alia, in the realm of remediation of pain.
  • An optimal mode of administration involves the use of atomizing inhalers. Integration of CBD and inhalers, utilizing currently known methods and formulations, manifest a number of significant shortcomings with respect to each of efficacious administration as well as both avoidance of adulteration and reasonable shelf life of all presently known inhaler-contained, to-be-administered CBD formulations.
  • inhaler-based CBD products are, by their formulations, manufacturing methodologies and post-production age by the time of their use, less efficacious that the present inventors have determined that CBD products otherwise could be, elicit unpleasant side-effects for users, and fail even to meet regulatory product adulteration standards.
  • CBD cannabidiol
  • the present inventors here disclose a novel and unobvious crystallization process to efficiently produce pH-balanced CBD in an oxygen-free environment that is optimally delivered in a metered-dose inhaler, without re-engineering the typical droplet size which is otherwise essential in the efficacious use of any systemic inhaler.
  • the process of the present invention is a crystallization work-up that creates a more properly balance pH/CBD isolate for use into an RTSL inhaler.
  • the present inventors have, through extensive research and testing, developed a CBD formulation and manufacturing process that addresses each of the above-described shortcoming of the present art.
  • the optimal steps in the here disclosed CBD product formulation methodology include:
  • the next step is the addition of a high temperature Hemp distillate. a. Note: The Hemp distillate must be greater than 80% CBD by volume.
  • Total % of Hemp Distillate will depend on maximum working volume of the JFR -20% working volume and -33% of n- Pentane for every 1 Kg of distillate and/or the amount of available material into the main body of the JFR).
  • the Huber Ministat 230 TCS is used for a 5L APICAL Filter reactor. Then set the TCS to 30° C to cool the jacket of the JFR. After 30° C is achieved, let agitate for -15 minutes. Next, mix 1 gram of potassium carbonate (K2CO3) with 2 grams of filter distilled water (D/H2O) by weight in a separate beaker until all the potassium is dissolved. Add the mixture into the main body of the JFR. a. Note: None add D/H2O or K2CO3 directly to the aqueous mixture without dissolving the K2CO3 in D/H2O. Agitate the homogenous solution for 15 to 20 minutes. Check for a pH value of 6 to 7.
  • step #6 if necessary, until the proper pH level is achieved.
  • pH of raw distillate varies from batch to batch. Lower the TCS to a jacket temperature of 25° C. After the jacket temperature reaches 25° C, agitate for -5 minutes. Continue to lower the jacket temperature by 5° C increments, remembering to let agitate for -5 minutes for every temperature change until the JFR reaches a temperature of 10° C. After 10° C is achieved in the JFR, let agitate for -5 minutes at -10° C. Then add 0.001% of CBD seeds. After adding the seeds to the main body of the JFR, agitate for -15 minutes. a. Note (%) will come from total volume weight of distillate and solvent combined.
  • the CBD material in the JFR is now ready for solvent rinsing.
  • Removal is accomplished by utilizing vacuum pump control and vacuum rated glass collection vessels. Start pulling out the rinsing solvent by vacuum through the vacuum rated glass vessel and bottom valve until there is no more solvents exiting the JFR. Once the vacuum control lines in the vacuum rated glass collection vessels and lines connected to the bottom valve are empty, the JFR is then empty of residual solvent and ready for the rinse. Repeat steps 13 and 14 at least 4 times or until the majority of the CBD wet- isolate is white with a little pink color. Next, take a sample of the isolate and send it to the analytical lab for HPLC testing. The sample must have a purification of 99+% purity. If not, more solvent rinses are necessary. Once the purity level is reached, move to next step. Offloading and Purification proceeds immediately after proper purity level is achieved.
  • the CBD product resulting from the above process represents a substantial improvement over any known CBD product in every respect in relation to product efficacy, shelf life, and user tolerance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de production d'un isolat de CBD à efficacité améliorée non adultéré pour une utilisation optimisée dans un inhalateur-doseur.
PCT/US2022/073669 2021-07-26 2022-07-13 Procédé de production d'isolat de cbd WO2023015102A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163259574P 2021-07-26 2021-07-26
US63/259,574 2021-07-26
US202217712091A 2022-04-02 2022-04-02
US17/712,091 2022-04-02

Publications (1)

Publication Number Publication Date
WO2023015102A1 true WO2023015102A1 (fr) 2023-02-09

Family

ID=85156394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/073669 WO2023015102A1 (fr) 2021-07-26 2022-07-13 Procédé de production d'isolat de cbd

Country Status (1)

Country Link
WO (1) WO2023015102A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2019100168A1 (fr) * 2017-11-27 2019-05-31 Enrico BOUCHARD Procédé de préparation d'une boisson terpénique à base de cannabis et boisson associée
US20190201809A1 (en) * 2015-01-22 2019-07-04 Phytoplant Research S.L. Methods of Purifying Cannabinoids Using Liquid:Liquid Chromatography
US20190307695A1 (en) * 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
US20210101856A1 (en) * 2019-09-20 2021-04-08 Marquette Analytica Cannabinoid processing methods and systems
US20210177914A1 (en) * 2019-12-11 2021-06-17 Cannabis Global, Inc. Cannabinoid enriched composition and method of using

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20190201809A1 (en) * 2015-01-22 2019-07-04 Phytoplant Research S.L. Methods of Purifying Cannabinoids Using Liquid:Liquid Chromatography
WO2019100168A1 (fr) * 2017-11-27 2019-05-31 Enrico BOUCHARD Procédé de préparation d'une boisson terpénique à base de cannabis et boisson associée
US20190307695A1 (en) * 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
US20210101856A1 (en) * 2019-09-20 2021-04-08 Marquette Analytica Cannabinoid processing methods and systems
US20210177914A1 (en) * 2019-12-11 2021-06-17 Cannabis Global, Inc. Cannabinoid enriched composition and method of using

Similar Documents

Publication Publication Date Title
McARTHUR The identification of pituitary interstitial cell stimulating hormone in human urine
Dignam et al. Effects of estrogens on renal hemodynamics and excretion of electrolytes in human subjects
WO2023015102A1 (fr) Procédé de production d'isolat de cbd
WO2023009442A1 (fr) Procédé pour cbg # 10 équilibré en ph
CN107952064A (zh) 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN104800172B (zh) 注射用卡络磺钠粉针剂和制法
HRP20020231A2 (en) ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
CN113087758B (zh) 源自蔓菁的碳环化合物的衍生物及其应用
CN106943410A (zh) 环黄芪醇（cag）在慢性肾功能衰竭药物中的用途
JP2024500166A (ja) クジノシド系化合物を含有する安定な液状医薬組成物
CN111647006B (zh) 头孢噻肟钠药物制剂及治疗包括伤寒和副伤寒的沙门菌感染适应症
US8815299B2 (en) Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds
CN107903245B (zh) 一种化合物及其在制备治疗类风湿性关节炎药物中的应用
CZ20021589A3 (cs) Deriváty ß-D-5-thioxylózy, způsob jejich přípravy a jejich terapeutické pouľití
CN107857754B (zh) 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
CN113788874B (zh) 黄体酮杂质的合成方法
WO2012019930A1 (fr) Méthode de traitement des stéatoses hépatiques et, en particulier, de la stéatohépatite non alcoolique
RU2777008C2 (ru) Состав hc-1119, способ его получения и применение
CN115487141A (zh) 一种布美他尼注射液组合物及其制备方法
CN107903253A (zh) 一种化合物、合成路线及其在制备预防/治疗类风湿性关节炎药物中的应用
TW201707709A (zh) 麥角固醇之用途
CN108299385A (zh) 一种化合物、合成路线及其在制备预防/治疗自身免疫性疾病药物中的应用
CN115252564A (zh) 一种注射用培美曲塞二钠的制备方法
CN117243888A (zh) 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法
CN108047239A (zh) 一种化合物、制备方法及其在制备预防/治疗自身免疫性疾病药物中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22854021

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE